Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase III Oncology
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
What is being tested: AZD5335 (a folate receptor alpha inhibitor) is compared against mirvetuximab soravtansine in FRα-high tumours and against chemotherapy in FRα-low tumours,…
21 Jul 2026 NCT07218809
● Recruiting
Post-market Evaluation of the Transition From the Baha Connect System to the Osia System in Adult Bone Conduction Implant Recipients
Study comparing safety and hearing improvement of newer Osia bone implant system versus older Baha Connect system in adults.
20 Jul 2026 NCT07130136
active not recruiting Phase III
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 – <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Remibrutinib versus placebo for adolescent chronic urticaria inadequately controlled by antihistamines, with long-term safety follow-up.
20 Jul 2026 NCT05677451
active not recruiting Phase II
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Tibulizumab tested against placebo over 24 weeks in systemic sclerosis patients, with all then receiving active drug for 28 weeks.
20 Jul 2026 NCT06843239
● Recruiting Phase III Oncology
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
What is being tested: The trial evaluates belzutifan (MK-6482), a targeted therapy already used for RCC, combined with zanzalintinib (a new investigational agent) to…
20 Jul 2026 NCT07489495
● Recruiting Oncology
β2M Post-HD Rebound Prediction
What is being tested: A predictive model for β2-microglobulin (β2M) rebound kinetics following haemodialysis, aiming to forecast post-dialysis β2M levels based on patient and…
20 Jul 2026 NCT07713680
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
GB-0895 is being tested as an add-on therapy for adolescents and adults with severe asthma that remains uncontrolled despite treatment with inhaled corticosteroids and…
20 Jul 2026 NCT07359846
● Recruiting Phase IV Oncology
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Drug being tested: Pirtobrutinib (LY3527727), a second-generation Bruton's tyrosine kinase (BTK) inhibitor, is being evaluated for long-term safety and tolerability in patients with previously…
20 Jul 2026 NCT07218341
● Recruiting Phase I Oncology
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Drug and mechanism: LOXO-783 is being tested as a targeted therapy for breast cancer and solid tumors with specific genetic mutations, representing a precision…
20 Jul 2026 NCT05307705
active not recruiting Phase III Oncology
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
New drug combination XL092 plus atezolizumab compared to regorafenib for advanced bowel cancer that hasn't responded to standard treatment.
17 Jul 2026 NCT05425940
active not recruiting Phase III
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
Brepocitinib, a new immune-suppressing drug, tested against placebo in adults with dermatomyositis over 52 weeks.
17 Jul 2026 NCT05437263
active not recruiting Phase III
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Garetosmab injection tested against placebo in adults with FOP to assess safety and effectiveness at slowing bone formation.
17 Jul 2026 NCT05394116
active not recruiting Phase I
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants
A safety and dose study of new drug UCB5285 in healthy people, including Japanese volunteers.
17 Jul 2026 NCT07286682
● Recruiting Phase I Gastroenterology
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
A new gene-editing treatment (VERVE-201) was tested in patients with severe high cholesterol to assess safety and whether it reduces cholesterol levels.
17 Jul 2026 NCT06451770
● Recruiting
Baseline Evaluation of Lymph Nodes in the Lower Quadrant Young People Using Point of Care Ultrasound (BELLY-POCUS)
Study establishing normal lymph node appearances on bedside ultrasound in children to help diagnose mesenteric adenitis.
17 Jul 2026 NCT07704814
active not recruiting Respiratory / COPD / Asthma
Is Hypoxemia Driving Outcome in Acute Hypoxemic Respiratory Failure? (HOMELAND Study)
Study examines whether low blood oxygen levels directly cause ICU deaths in respiratory failure patients, or if organ dysfunction is the real culprit.
17 Jul 2026 NCT07708506
● Recruiting Respiratory / COPD / Asthma
Longitudinal Population-based Observational Study of COVID-19 in the UK Population
What is being tested: COVIDENCE UK is an observational longitudinal study investigating risk factors for COVID-19 infection and adverse outcomes, whilst characterising the disease's…
17 Jul 2026 NCT04330599
● Recruiting Phase I Respiratory / COPD / Asthma
Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants
What is being tested: A controlled human infection model (CHIM) administering SARS-CoV-2 Omicron EG.5.1 variant via intranasal drops to evaluate breakthrough infections and immune…
17 Jul 2026 NCT07397455
● Recruiting Cardiology / Cardiovascular
Barts Endocarditis Research Registry
What is being tested: The registry evaluates infective endocarditis (IE) characteristics, current imaging practices, and implementation of European Society of Cardiology (ESC) guidelines in…
17 Jul 2026 NCT06434012
● Recruiting Oncology
Exercise to Improve Outcomes in Pancreatic Cancer
What is being tested: A structured exercise programme delivered before and after Whipple's procedure (pancreatic cancer surgery) to determine whether prehabilitation and postoperative exercise…
17 Jul 2026 NCT07710495
active not recruiting Phase I / Phase II
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Single-dose gene therapy injection for wet age-related macular degeneration, with safety and vision outcomes tracked over five years.
16 Jul 2026 NCT06660667
● Recruiting Cardiology / Cardiovascular
Left Ventricular Thrombus Registry
Registry studying blood clots in weakened hearts after heart attack or heart failure to improve future treatment strategies.
16 Jul 2026 NCT06963567
● Recruiting Phase III
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
Cenegermin eye drops versus placebo for treating persistent corneal erosion, measuring complete healing at four weeks.
16 Jul 2026 NCT07519902
active not recruiting Phase III Oncology
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Zolbetuximab plus chemotherapy versus placebo plus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction cancer positive for Claudin 18.2.
16 Jul 2026 NCT03653507
● Recruiting
MEASuRE: Metreleptin Effectiveness And Safety Registry
A registry tracking safety and effectiveness of metreleptin treatment in patients across the US and Europe.
16 Jul 2026 NCT02325674
● Recruiting Phase III Oncology
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
What is being tested: Oral upadacitinib (a JAK inhibitor) is being evaluated for safety and efficacy in treating moderate to severe hidradenitis suppurativa in…
16 Jul 2026 NCT05889182
● Recruiting Phase II
A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy
Surlorian tested against placebo for improving muscle strength and safety in adults with genetic RYR1-related muscle disease.
15 Jul 2026 NCT07560020
active not recruiting Cardiology / Cardiovascular
Precision Detection and Prediction of Atrial Arrhythmias Using Artificial Intelligence and Consumer Wearable Devices
AI-powered smartwatch analysis to improve atrial fibrillation detection and prediction in UK patients.
15 Jul 2026 NCT07291570
active not recruiting Phase III Neurology
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Ocrelizumab versus fingolimod for treating multiple sclerosis in children and teenagers over 24 weeks.
15 Jul 2026 NCT05123703
● Recruiting
Evaluation of Community Food Markets in Glasgow, Scotland.
Community food markets in Glasgow are being tested to see if they help low-income families buy and eat more fresh, healthy food.
15 Jul 2026 NCT07704736
active not recruiting Phase I
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
Phase 1 trial testing a new drug (GSK4771261) in healthy people and those with polycystic kidney disease to assess safety and effectiveness.
15 Jul 2026 NCT06734234
● Recruiting Phase III Oncology
VO and Nivolumab vs Physician’s Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
IGNYTE-3 Trial Summary VO plus nivolumab versus standard treatment for melanoma that progressed after checkpoint inhibitor therapy.
15 Jul 2026 NCT06264180
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
What is being tested: Tolvaptan (a vasopressin V2-receptor antagonist) is being evaluated for safety and pharmacodynamic effects in infants and children aged 28 days…
15 Jul 2026 NCT04782258
● Recruiting Phase III Diabetes / Metabolic
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
What is being tested: Ribupatide (KAI-9531), a once-weekly subcutaneous injection, is being evaluated for its efficacy in reducing body weight and improving glycaemic control…
15 Jul 2026 NCT07284901
● Recruiting Phase III Diabetes / Metabolic
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
Being tested: Elecoglipron (a novel therapeutic agent) versus placebo in patients with type 2 diabetes who have impaired renal function, all receiving background dapagliflozin…
15 Jul 2026 NCT07662135
● Recruiting Phase III Diabetes / Metabolic
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
What is being tested: The study investigates a dual-agent combination therapy of elecoglipron (a GLP-1 receptor agonist) plus dapagliflozin (an SGLT2 inhibitor) versus each…
15 Jul 2026 NCT07662109
● Recruiting Cardiology / Cardiovascular
Avr Thrombosis OutcoMe Study
What is being tested: Novel blood biomarkers that assess thrombosis and thrombolysis activity to identify patients at high risk of thrombotic complications following surgical…
15 Jul 2026 NCT04234841
● Recruiting Cardiology / Cardiovascular
“Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment” (PROTECT-HF)
What is being tested: PROTECT-HF compares right ventricular (RV) pacing—the established standard treatment for bradycardia—against physiological pacing approaches to determine which strategy produces better…
15 Jul 2026 NCT05815745
● Recruiting Phase III Oncology
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
What is being tested: The iFIT trial evaluates personalised treatment strategies for newly diagnosed myeloma patients who are ineligible for stem cell transplantation, with…
15 Jul 2026 NCT07649525
● Recruiting Phase III
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
A drug called zeleciment basivarsen was tested to see if it safely and effectively treats myotonic dystrophy type 1.
14 Jul 2026 NCT07486934
active not recruiting Phase II Oncology
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
Trial testing whether adding experimental drugs to tislelizumab improves outcomes in advanced head and neck cancer patients.
14 Jul 2026 NCT05909904
active not recruiting Phase I / Phase II Oncology
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Early-stage trial testing JNJ-63723283 (anti-PD-1 antibody) to find safe doses and effectiveness across multiple advanced cancers.
14 Jul 2026 NCT02908906
active not recruiting Phase II
Study of INBRX-109 in Conventional Chondrosarcoma
Experimental drug INBRX-109 tested against placebo in patients with advanced chondrosarcoma that cannot be surgically removed.
14 Jul 2026 NCT04950075
active not recruiting Phase III Oncology
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Durvalumab alone or combined with tremelimumab compared to chemotherapy for advanced bladder cancer.
14 Jul 2026 NCT02516241
● Recruiting Phase III
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Eptinezumab reduced migraine days more than placebo in teenagers aged 12-17 with chronic migraine.
14 Jul 2026 NCT04965675
● Recruiting Phase III
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Ruxolitinib cream safely and effectively treats vitiligo in children aged 6-12 years.
14 Jul 2026 NCT06804811
active not recruiting Phase III
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
A drug injected under the skin was tested to see if it could reduce kidney damage and was safe in patients with IgA nephropathy.
14 Jul 2026 NCT05248646
● Recruiting Diabetes / Metabolic
Magnetic Resonance Imaging Assessment of Multiorgan Health in Obesity
GLP-1 drugs plus lifestyle changes versus lifestyle alone for weight loss and organ health improvement in obese teenagers.
14 Jul 2026 NCT07702825
● Recruiting Phase III
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Eptinezumab reduced migraine days in children with episodic migraine.
14 Jul 2026 NCT05897320
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
What is being tested: Elecoglipron, a novel investigational drug, is being evaluated against oral semaglutide (an established GLP-1 receptor agonist) for efficacy, safety, and…
14 Jul 2026 NCT07662213